Apolipoprotein C-III is linked to the insulin resistance and beta-cell dysfunction that are present in rheumatoid arthritis.
Apolipoprotein C-III
Beta-cell dysfunction
Insulin resistance
Rheumatoid arthritis
Journal
Arthritis research & therapy
ISSN: 1478-6362
Titre abrégé: Arthritis Res Ther
Pays: England
ID NLM: 101154438
Informations de publication
Date de publication:
30 05 2022
30 05 2022
Historique:
received:
06
12
2021
accepted:
21
05
2022
entrez:
31
5
2022
pubmed:
1
6
2022
medline:
3
6
2022
Statut:
epublish
Résumé
Insulin resistance and beta-cell dysfunction are manifestations of rheumatoid arthritis (RA). Apolipoprotein C-III (ApoC3) has been associated with such insulin resistance and beta-cell dysfunction in the general population. Our purpose was to study whether ApoC3 is also related to the insulin resistance and beta-cell dysfunction that are present in patients with RA. Three hundred thirty-eight non-diabetic patients with RA who had a glycemia lower than 110 mg/dl were recruited. Insulin, C-peptide, and ApoC3 were assessed. Insulin resistance and beta-cell function were calculated using the Homeostasis Model Assessment (HOMA2) indices. A multivariable regression analysis was performed to study the relationship of ApoC3 with those molecules and indices adjusting for classic factors associated with insulin resistance that included glucocorticoids. ApoC3 was related to significant higher levels of circulating insulin (beta coef. 0.37 [95%CI 0.01-0.73] µU/ml, p = 0.044) and C-peptide (beta coef. 0.13 [95%CI 0.05-0.22] ng/ml, p = 0.003), and higher insulin resistance -HOMA2-IR- (beta coef. 0.05 [95%CI 0.00-0.09], p = 0.041) and beta-cell dysfunction -HOMA2-%B- (beta coef. 2.94 [95%CI 0.07-5.80], p = 0.044) indices. This was found after a fully multivariable analysis that included, among others, prednisone intake and the classic factors associated with carbohydrate metabolism such as triglycerides, waist circumference, and obesity. ApoC3, insulin resistance, and beta-cell dysfunction are independently associated in patients RA.
Sections du résumé
BACKGROUND
Insulin resistance and beta-cell dysfunction are manifestations of rheumatoid arthritis (RA). Apolipoprotein C-III (ApoC3) has been associated with such insulin resistance and beta-cell dysfunction in the general population. Our purpose was to study whether ApoC3 is also related to the insulin resistance and beta-cell dysfunction that are present in patients with RA.
METHODS
Three hundred thirty-eight non-diabetic patients with RA who had a glycemia lower than 110 mg/dl were recruited. Insulin, C-peptide, and ApoC3 were assessed. Insulin resistance and beta-cell function were calculated using the Homeostasis Model Assessment (HOMA2) indices. A multivariable regression analysis was performed to study the relationship of ApoC3 with those molecules and indices adjusting for classic factors associated with insulin resistance that included glucocorticoids.
RESULTS
ApoC3 was related to significant higher levels of circulating insulin (beta coef. 0.37 [95%CI 0.01-0.73] µU/ml, p = 0.044) and C-peptide (beta coef. 0.13 [95%CI 0.05-0.22] ng/ml, p = 0.003), and higher insulin resistance -HOMA2-IR- (beta coef. 0.05 [95%CI 0.00-0.09], p = 0.041) and beta-cell dysfunction -HOMA2-%B- (beta coef. 2.94 [95%CI 0.07-5.80], p = 0.044) indices. This was found after a fully multivariable analysis that included, among others, prednisone intake and the classic factors associated with carbohydrate metabolism such as triglycerides, waist circumference, and obesity.
CONCLUSION
ApoC3, insulin resistance, and beta-cell dysfunction are independently associated in patients RA.
Identifiants
pubmed: 35637531
doi: 10.1186/s13075-022-02822-w
pii: 10.1186/s13075-022-02822-w
pmc: PMC9150381
doi:
Substances chimiques
APOC3 protein, human
0
Apolipoprotein C-III
0
C-Peptide
0
Insulin
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
126Informations de copyright
© 2022. The Author(s).
Références
Diabetes Metab Res Rev. 2019 Mar;35(3):e3118
pubmed: 30557902
Arthritis Rheumatol. 2017 May;69(5):943-952
pubmed: 28029752
Curr Atheroscler Rep. 2016 Oct;18(10):59
pubmed: 27613744
Clin Exp Rheumatol. 2005 Sep-Oct;23(5 Suppl 39):S100-8
pubmed: 16273793
Diabetes. 2007 Jun;56(6):1718-26
pubmed: 17369522
J Rheumatol. 2014 Apr;41(4):658-65
pubmed: 24532832
Lipids Health Dis. 2020 Jun 2;19(1):121
pubmed: 32487177
Diabetes. 2004 Dec;53 Suppl 3:S16-21
pubmed: 15561905
J Rheumatol. 2021 Mar;48(3):339-347
pubmed: 32541071
Arthritis Rheum. 2010 Sep;62(9):2569-81
pubmed: 20872595
Rheumatology (Oxford). 2003 Feb;42(2):244-57
pubmed: 12595618
J Rheumatol. 2019 Mar;46(3):229-236
pubmed: 30275261
Arthritis Res Ther. 2015 Mar 06;17:45
pubmed: 25884688
Front Endocrinol (Lausanne). 2013 Mar 27;4:37
pubmed: 23542897
Proc Natl Acad Sci U S A. 2015 May 19;112(20):E2611-9
pubmed: 25941406
Clin Exp Rheumatol. 2019 May-Jun;37(3):373-379
pubmed: 30299246
Arthritis Care Res (Hoboken). 2012 Jul;64(7):993-1000
pubmed: 22337612
Nat Immunol. 2020 Jan;21(1):30-41
pubmed: 31819254
Clin Exp Rheumatol. 2018 May-Jun;36(3):421-427
pubmed: 29352842
Cell. 2012 Mar 16;148(6):1160-71
pubmed: 22424227
Arthritis Res Ther. 2017 Oct 17;19(1):229
pubmed: 29041949
Diabetes Care. 2004 Jun;27(6):1487-95
pubmed: 15161807
Arthritis Rheum. 1995 Jan;38(1):44-8
pubmed: 7818570